Industry experts address 150 healthcare professionals at Quality in Primary Care Globalpharma seminar

Around 150 healthcare professionals from the UAE, Saudi Arabia and Iraq attended the interactive seminar

  
Industry experts address 150 healthcare professionals at Quality in Primary Care Globalpharma seminar

Dubai:Globalpharma, a pharmaceutical company wholly-owned by Dubai Investments PJSC and a market leader in several generic medicines, hosted a ‘Quality in Primary Care’ healthcare symposium in Dubai. The event underlined Globalpharma’s commitment to supporting healthcare professionals in the UAE and region by strengthening their knowledge and skills, part of its long-term focus on promotion Continuous Medical Education (CME).

Around 150 healthcare professionals from the UAE, Saudi Arabia and Iraq attended the interactive seminar at which 12 experts in six therapy areas addressed the audience on latest updates, trends and findings. Attendees, who were involved throughout via an interactive, multiple choice quiz component during each session, gained six CME credit hours by the Dubai Health Authority.

The six therapy areas covered by the 12 healthcare experts were: ‘Diabetic Dyslipidemia’, ‘Management of Hypertension & CVD High-Risk Patients, ‘Management of Chronic Pain & Sports Injury, ‘Updates on the Management of Urinary Tract Infections and Erectile Dysfunction,’ ‘Current Trends, Guidelines and Challenges in the Management of GERD and H-Pylori,’ and ‘Management of Allergic Rhinitis and Rhinosinusitis’.

Globalpharma is a wholly owned subsidiary of Dubai Investments. Established in 1998 and headquartered in Dubai Investments Park, Globalpharma grew to become a market leader in certain generic medicines with a strong regional footprint. Globalpharma manufactures and markets pharmaceutical products in more than 14 countries across the GCC, Middle East and neighbouring markets.

Globalpharma manufactures and commercializes pharmaceutical products under CGMP (current good manufacturing practice) conditions including antibiotics, cardiovascular, anti-ulcerants, analgesic, NSAIDs (Nonsteroidal anti-inflammatory drugs), food supplements, vitamins, anti-diabetics, respiratory products and anti-histamine formulations.

© Press Release 2019

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases